NASDAQ
27.03USD
+1.06 (+4.08%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.9B
P/E
—
EPS
—
Beta
0.00
52W range
24.61-32
Day range
25.24–27.15
Open
25.92
Prev close
25.97
Volume
329.8K
Avg volume
1.3M
Dividend
0.00
IPO
2026-08-06
https://www.globenewswire.com/news-release/2026/08/06/3339895/0/en/Braveheart-Bio-Announces-Pricing-of-Upsized-Initial-Public-Offering.html · 8/6/2026+0.80
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
